人源化BCMA CAR-T挽救治疗鼠源CAR-T后进展的RRMM两例
两例难治性多发性骨髓瘤患者经鼠源BCMA CAR-T治疗后分别于16和18个月疾病进展,其中例1出现髓外病变。再次输注人源化BCMA CAR-T后分别达部分缓解和非常好的部分缓解,例1髓外病变4个月消失,安全性可控。
要点
- 鼠源BCMA CAR-T后进展的RRMM可考虑人源化BCMA CAR-T挽救治疗
- 人源化BCMA CAR-T后CRS和ICANS级别可能高于鼠源CAR-T,需支持治疗
- 人源化BCMA CAR-T对原代MM细胞毒作用优于鼠源CAR-T(P<0.001)
核心结论
- 人源化BCMA CAR-T细胞治疗对鼠源CAR-T后疾病进展的RRMM患者有效且安全性可控。
- 对伴有髓外病变的患者可能尤其有效。
研究设计与样本
- 两例RRMM患者采集自体外周血单个核细胞制备BCMA CAR-T细胞。
- FC方案预处理后分别予鼠源和人源化BCMA CAR-T细胞输注。
- 输注后监测CAR-T细胞扩增、细胞因子变化及不良反应。
- 体外试验检测转染效率、对MM细胞株杀伤活力及炎症细胞因子释放水平。
主要发现
- 例1和例2输注鼠源CAR-T后3个月分别为CR和疾病稳定(SD)。
- 16和18个月后疾病进展,例1出现髓外病变。
- 人源化BCMA CAR-T挽救治疗后例1达PR、例2达VGPR,例1髓外病变4个月消失。
- 人源化BCMA CAR-T治疗期间CAR-T细胞体内扩增峰值和持续时间均高于鼠源治疗期间。
- 人源化BCMA CAR-T治疗期间IL-6、IL-8、IL-10、IFN-γ及TNF-α峰值高于鼠源CAR-T峰值。
关键数值与推荐
- 鼠源CAR-T治疗期间两例患者CRS均为1级,无ICANS。
- 人源化CAR-T治疗例1 CRS为3级、ICANS为2级,支持对症治疗后好转;例2 CRS 2级,无ICANS。
- 48小时效靶比1∶1时BCMA(+)肿瘤细胞残余比例:例1人源化(17.38±5.18)% vs 鼠源(28.27±4.58)%;例2人源化(13.25±1.62)% vs 鼠源(22.77±1.77)%。
- 人源化BCMA CAR-T对原代MM细胞毒作用优于鼠源CAR-T(P<0.001)。
- 人源化BCMA CAR-T的IFN-γ、TNF-α及IL-6释放水平均高于鼠源CAR-T(P值均<0.001)。
临床怎么用
- 对鼠源BCMA CAR-T后进展的RRMM患者,可评估人源化BCMA CAR-T挽救治疗。
- 人源化BCMA CAR-T治疗后需密切监测CRS和ICANS,及时支持对症处理。
局限性
- 仅两例患者,样本量小。
- 为观察性研究,无对照组。
- 随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the efficacy and safety of humanized anti-BCMA chimeric antigen receptor modified (BCMA CAR) -T cell therapy after disease progression with their murine BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (MM) . Methods: Study participants underwent leukapheresis to collect T cells for BCMA CAR-T manufacturing. Patients were pretreated with intensive chemotherapy (fludarabine combined with cytarabine) before CAR-T therapy. Adverse events (AEs) , CAR DNA expansion, and cytokine were monitored. In vitro, transfection efficacy, specific cytotoxicity, and inflammatory response were detected when co-cultured with effector and target cells. Results: Patient (PT) 1 and 2 achieved complete remission (CR) and disease stability at 3 months post murine CAR-T therapy. However, 16 and 18 months later, they experienced progression of disease (PD) , and patient 1 presented with extramedullary disease at PD. Both of the patients received humanized CAR-T therapy and achieved partial remission (PR) and very good partial remission (VGPR) post humanized CAR-T therapy. PT1 achieved CR of the soft tissue masses at 4 months post humanized CAR-T therapy. Notably, the median peak of the BCMA CAR-T cells, copy of BCMA CAR gene, persistence of BCMA CAR-T, and the peak levels of IL-6, IL-8, IL-10, IFN-γ and TNF-α were higher in humanized CAR-T therapy than those in the murine CAR-T therapy. During the murine CAR-T therapy, both of the patients experienced grade 1 CRS and no ICANS. PT1 experienced grade 3 CRS and grade 2 ICANS during humanized CAR-T therapy, which were relieved by supportive care. Grade 2 CRS was observed for patient 2 during humanized CAR-T therapy. Humanized BCMA CAR-T cells showed a higher inflammatory response and in vitro cytotoxicity than that of murine BCMA CAR-T cells with effector/targets cells at 1∶1 over 48 hours (P<0.001) . The proportions of residual cells in humanized BCMA CAR-T and murine CAR-T were (17.38±5.18) % vs (28.27±4.58) %, (13.25±1.62) % vs (22.77±1.77) % for PT1 and PT2, respectively. Conclusions: The humanized BCMA CAR-T cell therapy was efficient and safe for patients who experienced progression of disease after the murine CAR-T therapy, especially for patients with extramedullary disease. 目的: 探讨人源化B细胞成熟抗原(BCMA)嵌合抗原受体T细胞(CAR-T细胞)治疗鼠源BCMA CAR-T后疾病再进展的难治性多发性骨髓瘤(RRMM)患者临床疗效及安全性。 方法: 采集两例患者自体外周血单个核细胞,制备BCMA CAR-T细胞,FC方案(氟达拉滨+环磷酰胺)预处理后分别予鼠源/人源化BCMA CAR-T细胞输注。输注后监测CAR-T细胞扩增、细胞因子变化及不良反应。体外试验检测鼠源/人源化BCMA CAR-T转染效率、对MM细胞株的杀伤活力及炎症细胞因子释放水平。 结果: 例1及例2输注鼠源CAR-T后3个月分别为完全缓解(CR)及疾病稳定(SD)。16个月及18个月后出现疾病再进展,且例1出现髓外病变,输注人源化BCMA CAR-T细胞挽救治疗后,分别达到部分缓解(PR)及非常好的部分缓解(VGPR)的疗效,例1髓外病变4个月消失。两例患者在人源化BCMA CAR-T细胞治疗期间,CAR-T细胞体内扩增峰值、体内持续时间均较鼠源输注期间水平升高。人源化BCMA CAR-T治疗期间IL-6、IL-8、IFN-γ、IL-10及TNF-α峰值高于鼠源CAR-T峰值。两例患者输注鼠源CAR-T期间细胞因子释放综合征(CRS)均为1级,无神经系统毒性(ICANS);人源化CAR-T治疗例1 CRS为3级,ICANS为2级,支持对症治疗后好转,例2 CRS 2级,无ICANS发生。体外试验证实48 h效靶比为1∶1时,人源化BCMA CAR-T、鼠源CAR-T细胞分别与例1、例2患者共培养,BCMA(+)肿瘤细胞残余比例分别为(17.38±5.18)%对(28.27±4.58)%、(13.25±1.62)%对(22.77±1.77)%,人源化BCMA-CAR-T对原代MM的细胞毒作用优于鼠源CAR-T细胞(P<0.001),且IFN-γ、TNF-α及IL-6释放水平均高于鼠源CAR-T细胞(P值均<0.001)。 结论: 鼠源BCMA CAR-T治疗后复发进展的RRMM患者再次输注人源BCMA CAR-T可能有效且安全性可控。.
引用
- Cui R, Li P, Li Q, et al. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34384157. doi:10.3760/cma.j.issn.0253-2727.2021.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。